The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of patients with brain metastases (BM) from renal cell cancer (RCC).
David Naskhletashvili
No relevant relationships to disclose
Vera Gorbunova
No relevant relationships to disclose
Mark Bychkov
No relevant relationships to disclose
Ali Bekyashev
No relevant relationships to disclose
Vladislav Karahan
No relevant relationships to disclose
Vladimir Aloshin
No relevant relationships to disclose
Zoya Michina
No relevant relationships to disclose
Sergey Medvedev
No relevant relationships to disclose
Evgeny Prozorenko
No relevant relationships to disclose
Alla Markovich
No relevant relationships to disclose